Inventor · disambiguated record
Stephen B. Ruddy
Also filed as: RUDDY STEPHEN · RUDDY STEPHEN B
38 granted patents·26 pending applications·3,870 citations·filing 1994–2020
98Inventor score
Files withELAN PHARMA INT LTD24SHIRE VIROPHARMA INC7STERLING WINTHROP INC6ALKERMES PHARMA IRELAND LTD5FOURNIER LAB IRELAND LTD3
Top patents by PatentIndex Score
64 records- 0199US6908626B2Compositions having a combination of immediate release and controlled release characteristicsELAN PHARMA INT LTD·Filed 2002·Granted Jun 21, 2005·167 cites·34 claims
- 0299US6592903B2Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinateELAN PHARMA INT LTD·Filed 2002·Granted Jul 15, 2003·216 cites·33 claims
- 0399US6375986B1Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinateELAN PHARMA INT LTD·Filed 2000·Granted Apr 23, 2002·349 cites·34 claims
- 0497US6432381B2Methods for targeting drug delivery to the upper and/or lower gastrointestinal tractELAN PHARMA INT LTD·Filed 1997·Granted Aug 13, 2002·214 cites·27 claims
- 0597US6045829ANanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizersELAN PHARMA INT LTD·Filed 1997·Granted Apr 4, 2000·329 cites·22 claims
- 0697US5580579ASite-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymersNANO SYS LLC·Filed 1995·Granted Dec 3, 1996·357 cites·15 claims
- 0796US6221400B1Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitorsELAN PHARMA INT LTD·Filed 1999·Granted Apr 24, 2001·215 cites·13 claims
- 0896US5628981AFormulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agentsNANO SYS LLC·Filed 1994·Granted May 13, 1997·172 cites·10 claims
- 0996US5585108AFormulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable claysNANOSYSTEMS LLC·Filed 1994·Granted Dec 17, 1996·244 cites·4 claims
- 1095US6316029B1Rapidly disintegrating solid oral dosage formFLAK PHARMA INTERNATIONAL LTD·Filed 2000·Granted Nov 13, 2001·412 cites·70 claims
- 1195US5718919ANanoparticles containing the R(-)enantiomer of ibuprofenNANOSYSTEMS LLC·Filed 1995·Granted Feb 17, 1998·259 cites·3 claims
- 1294US10080788B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2017·Granted Sep 25, 2018·4 cites·30 claims
- 1394US9616111B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2015·Granted Apr 11, 2017·12 cites·18 claims
- 1494US7320802B2Methods of treatment using nanoparticulate fenofibrate compositionsELAN PHARMA INT LTD·Filed 2003·Granted Jan 22, 2008·54 cites·396 claims
- 1594US7198795B2In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositionsELAN PHARMA INT LTD·Filed 2002·Granted Apr 3, 2007·62 cites·19 claims
- 1694US5466440AFormulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable claysEASTMAN KODAK CO·Filed 1994·Granted Nov 14, 1995·155 cites·8 claims
- 1793US7276249B2Nanoparticulate fibrate formulationsFOURNIER LAB IRELAND LTD·Filed 2003·Granted Oct 2, 2007·61 cites·189 claims
- 1893US6068858AMethods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizersELAN PHARMA INTERNATIONAL LIMI·Filed 1999·Granted May 30, 2000·232 cites·18 claims
- 1993US5593657ABarium salt formulations stabilized by non-ionic and anionic stabilizersNANOSYSTEMS LLC·Filed 1995·Granted Jan 14, 1997·161 cites·22 claims
- 2091US10201595B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2017·Granted Feb 12, 2019·2 cites·30 claims
- 2191US10130690B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2017·Granted Nov 20, 2018·2 cites·29 claims
- 2291US10105423B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2017·Granted Oct 23, 2018·2 cites·29 claims
- 2388US7695739B2In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositionsELAN PHARMA INT LTD·Filed 2007·Granted Apr 13, 2010·6 cites·18 claims
- 2488US5503723AIsolation of ultra small particlesEASTMAN KODAK CO·Filed 1995·Granted Apr 2, 1996·107 cites·7 claims
- 2587US11364288B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencyVIROPHARMA BIOLOGICS LLC·Filed 2019·Granted Jun 21, 2022·1 cites·8 claims
- 2687US7927627B2Nanoparticulate fibrate formulationsELAN PHARMA INT LTD·Filed 2007·Granted Apr 19, 2011·7 cites·20 claims
- 2785US8623412B2Abuse-resistant pharmaceutical compositionsVAGHEFI FARID·Filed 2003·Granted Jan 7, 2014·25 cites·7 claims
- 2885US7998507B2Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitorsELAN PHARMA INT LTD·Filed 2005·Granted Aug 16, 2011·6 cites·35 claims
- 2984US7931917B2Nanoparticulate fibrate formulationsELAN PHARMA INT LTD·Filed 2007·Granted Apr 26, 2011·5 cites·30 claims
- 3082US8309136B2In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositionsCOOPER EUGENE R·Filed 2010·Granted Nov 13, 2012·3 cites·14 claims
- 3175US2009155331A1Injectable nanoparticulate olanzapine formulationsELAN PHARMA INT LTD·Filed 2008·Application pending·0 cites
- 3274US11534482B2C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiencyVIROPHARMA BIOLOGICS LLC·Filed 2018·Granted Dec 27, 2022·0 cites·35 claims
- 3374US2019160158A1C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2018·Application pending·0 cites
- 3472US2009130213A1Rapidly disintegrating solid oral dosage formELAN PHARMA INT LTD·Filed 2007·Application pending·0 cites
- 3572US2008213371A1Rapidly disintegrating solid oral dosage formELAN PHARMA INT LTD·Filed 2008·Application pending·0 cites
- 3669US2017224788A1C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiencySHIRE VIROPHARMA INC·Filed 2017·Application pending·0 cites
- 3768US2013309310A1Injectable Nanoparticulate Olanzapine FormulationsALKERMES PHARMA IRELAND LTD·Filed 2013·Application pending·0 cites
- 3867US2014248341A1Alcohol resistant enteric pharmaceutical compositionsALKERMES PHARMA IRELAND LTD·Filed 2014·Application pending·0 cites
- 3963US2004057993A1Rapidly disintegrating solid oral dosage formELAN PHARMA INT LTD·Filed 2003·Application pending·0 cites
- 4063US2012114754A1Rapidly disintegrating solid oral dosage formJAIN RAJEEV A·Filed 2011·Application pending·0 cites
- 4162US2018085315A1Alcohol resistant enteric pharmaceutical compositionsALKERMES PHARMA IRELAND LTD·Filed 2017·Application pending·0 cites
- 4261US2008138424A1Nanoparticulate fibrate formulationsFOURNIER LAB IRELAND LTD·Filed 2007·Application pending·0 cites
- 4361US2015238505A1Injectable nanoparticulate olanzapine formulationsALKERMES PHARMA IRELAND LTD·Filed 2015·Application pending·0 cites
- 4459US2021038585A1Niraparib formulationsTESARO INC·Filed 2020·Application pending·0 cites
- 4559US2003054045A1Formulations for therapeutic agents absorbed through mucous membranesELAN PHARMA INT LTD·Filed 2002·Application pending·0 cites
- 4658US2011223244A1Alcohol resistant enteric pharmaceutical compositionsELAN PHARMA INT LTD·Filed 2011·Application pending·0 cites
- 4757US2012315336A1Injectable nanoparticulate olanzapine formulationsRUDDY STEPHEN B·Filed 2012·Application pending·0 cites
- 4856US2004013613A1Rapidly disintegrating solid oral dosage formFiled 2001·Application pending·0 cites
- 4952US2014112980A1Abuse-resistant pharmaceutical compositionsELAN PHARMA INT LTD·Filed 2013·Application pending·0 cites
- 5052US2003215502A1Fast dissolving dosage forms having reduced friabilityELAN PHARMA INT LTD·Filed 2003·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Stephen B. Ruddy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →